BioCentury | Nov 23, 2020
Product Development

Immunocore charts the path for bispecifics in solid tumors with Phase III readout

With a positive Phase III readout in metastatic uveal melanoma, Immunocore has become the first company to solve one of the biggest challenges in immuno-oncology: applying T cell-engaging bispecifics to solid tumors.  The data suggest...
BioCentury | Nov 18, 2020
Emerging Company Profile

InterVenn: liquid biopsy diagnostics based on glycoproteins

InterVenn is tapping the glycoproteome for new markers for blood-based cancer diagnostics and using machine learning to accelerate the biomarker discovery process.  The company announced Monday that...
BioCentury | Oct 21, 2020

Seeking programs underserved by traditional VCs, MD Anderson launches fund to support trials

A new fund co-founded by MD Anderson is intended to support early development of a subset of drug candidates that are not served by traditional venture capital or biopharmas, but which the cancer research...
BioCentury | Sep 25, 2020

Sept. 24 Quick Takes: AveXis vets steer Taysha to IPO; plus Exact Sciences, Monte Rosa, OBiO, Moderna, Immetas and more

Taysha raises $157M in IPOShares of Taysha Gene Therapies Inc. (NASDAQ:TSHA) rose $4.06 (20%) to $24.06 in the CNS disorders company’s first day of trading, after it raised $157 million in an upsized IPO through the sale...
BioCentury | Sep 18, 2020

With details on lead sialoglycan degrader in place, Palleon raises $100M series B

Having nominated a lead program, identified top indications and sorted out manufacturing, Palleon raised a $100 million series B round to bring its enzymatic sialoglycan degrader to the clinic for cancer....
BioCentury | Aug 27, 2020
Distillery Therapeutics

A collagen receptor as an Alzheimer’s target

DISEASE CATEGORY: Neurology INDICATION: Alzheimer’s disease (AD) Blocking the collagen receptor GP6 could treat Alzheimer’s disease by reducing platelet-associate β amyloid aggregation. In vitro, platelets...
BioCentury | Aug 12, 2020
Product Development

Aug. 11 Quick Takes: BMS hits, Genentech misses; plus JW-Lyell, CStone, Big Health

Opdivo clears Phase III hurdles in gastric, esophageal cancers Opdivo nivolumab from Bristol Myers Squibb Co. (NYSE:BMY) plus chemotherapy led to a survival benefit compared with chemotherapy alone in the Phase III CheckMate -649 trial as first-line...
BioCentury | Jul 23, 2020

July 22 Quick Takes: BioNTech raises $512M; plus Vesigen, Quantro, Cullinan, TransThera, JW-Syracuse, AnHeart-NewG

BioNTech prices upsized financing BioNTech SE (NASDAQ:BNTX) raised $511.5 million in an upsized offering through the sale of 5.5 million ADSs at $93 per ADS. The deal, which had been slated for 5 million ADSs,...
BioCentury | Jul 23, 2020

Elevation debuts with tumor-agnostic mAb in Phase II

Led by former Loxo Chairman Steve Elms, Elevation emerged from stealth Tuesday with a registration-enabling trial of a tissue-agnostic cancer therapy and a handful of diagnostics partners. Elevation Oncology Inc. is developing therapies for cancers...
BioCentury | Jul 15, 2020
Product Development

Repurposing hopes for Tavalisse in COVID-19 breathe life into Rigel shares

Rigel is the latest beneficiary of investor exuberance for COVID-19 plays. Shares of Rigel Pharmaceuticals Inc. (NASDAQ:RIGL) gained 91% to $4.12, giving the company a market cap of nearly $700 million, after it said on...
Items per page:
1 - 10 of 2029